CA2122473A1 - Dosage en phase liquide de proteines de la matrice nucleaire - Google Patents

Dosage en phase liquide de proteines de la matrice nucleaire

Info

Publication number
CA2122473A1
CA2122473A1 CA 2122473 CA2122473A CA2122473A1 CA 2122473 A1 CA2122473 A1 CA 2122473A1 CA 2122473 CA2122473 CA 2122473 CA 2122473 A CA2122473 A CA 2122473A CA 2122473 A1 CA2122473 A1 CA 2122473A1
Authority
CA
Canada
Prior art keywords
nuclear matrix
matrix protein
fluid assay
protein fluid
evaluating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2122473
Other languages
English (en)
Other versions
CA2122473C (fr
Inventor
Lee Anne Beausang
Graham P. Lidgard
Thomas E. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matritech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2122473A1 publication Critical patent/CA2122473A1/fr
Application granted granted Critical
Publication of CA2122473C publication Critical patent/CA2122473C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002122473A 1991-10-31 1992-10-29 Dosage en phase liquide de proteines de la matrice nucleaire Expired - Lifetime CA2122473C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78580491A 1991-10-31 1991-10-31
US785,804 1991-10-31
PCT/US1992/009220 WO1993009437A2 (fr) 1991-10-31 1992-10-29 Analyse de proteines matricielles nucleaires solubles dans les fluides corporels

Publications (2)

Publication Number Publication Date
CA2122473A1 true CA2122473A1 (fr) 1993-05-13
CA2122473C CA2122473C (fr) 2001-01-23

Family

ID=25136671

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002122473A Expired - Lifetime CA2122473C (fr) 1991-10-31 1992-10-29 Dosage en phase liquide de proteines de la matrice nucleaire

Country Status (9)

Country Link
US (8) US5840503A (fr)
EP (1) EP0642668B1 (fr)
JP (1) JP3190042B2 (fr)
AT (1) ATE191567T1 (fr)
AU (1) AU658257B2 (fr)
CA (1) CA2122473C (fr)
DE (1) DE69230890T2 (fr)
ES (1) ES2147555T3 (fr)
WO (1) WO1993009437A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230890T2 (de) * 1991-10-31 2000-12-07 Matritech Inc Bestimmung von nukleären matrixproteinen in flüssigkeiten
DE69333377T2 (de) * 1992-06-22 2004-10-21 Matritech Inc Neuartige marker maligner zelltypen in der inneren nukleären matrix
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
JPH10512158A (ja) * 1995-11-03 1998-11-24 ゲッツェンバーグ，ロバート・エイチ 膀胱の核マトリックスタンパク質ならびに細胞増殖性疾患の検出及び治療におけるその使用
US6280956B1 (en) 1995-11-03 2001-08-28 University Of Pittsburgh Antibodies to bladder cancer nuclear matrix proteins and their use
US5914238A (en) 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US6232443B1 (en) * 1997-04-08 2001-05-15 University Of Pittsburgh Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use
US7229772B1 (en) 1998-03-18 2007-06-12 Roche Diagnostics Gmbh Detection of apoptotic products
JP3517642B2 (ja) * 1998-03-18 2004-04-12 ロシュ ダイアグノスティックス ゲーエムベーハー アポトーシス産物の検出
CA2372783A1 (fr) 1999-05-17 2000-11-23 Pro Duct Health, Inc. Identification de substances provenant d'un canal galactophore
US20030228640A1 (en) * 1999-10-15 2003-12-11 University Of Pittsburgh Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
US6617432B1 (en) 1999-10-15 2003-09-09 University Of Pittsburgh Nuclear matrix proteins polynucleotide sequences encoding them and their use
KR100350111B1 (ko) 2000-02-22 2002-08-23 삼성전자 주식회사 반도체 장치의 배선 및 이의 제조 방법
US7654227B1 (en) * 2001-12-20 2010-02-02 Pat Yananton Absorbent pad for entrapping small and large particles, retaining liquids and eliminating odors
US7080373B2 (en) * 2001-03-07 2006-07-18 Freescale Semiconductor, Inc. Method and device for creating and using pre-internalized program files
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
JP4274856B2 (ja) * 2003-06-19 2009-06-10 オリンパス株式会社 Ｄｎａとｄｎａ結合タンパク質との反応を検出する方法
US7602845B2 (en) * 2003-09-23 2009-10-13 Nxp B.V. Adaptive filter
US7649988B2 (en) 2004-06-15 2010-01-19 Acoustic Technologies, Inc. Comfort noise generator using modified Doblinger noise estimate
US7935479B2 (en) 2004-07-19 2011-05-03 Cell Biosciences, Inc. Methods and devices for analyte detection
JP5073491B2 (ja) * 2004-07-19 2012-11-14 プロテインシンプル 分析対象物の検出のための方法
US7846676B2 (en) * 2004-07-19 2010-12-07 Cell Biosciences, Inc. Methods and devices for analyte detection
JP2008536128A (ja) * 2005-04-09 2008-09-04 セル バイオサイエンシズ，インコーポレイテッド 自動化微小体積アッセイシステム
US8333970B2 (en) 2005-05-18 2012-12-18 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
US20070015166A1 (en) * 2005-07-14 2007-01-18 Nilsen Thor W Lateral flow methods and devices for detection of nucleic acid binding proteins
US8945361B2 (en) 2005-09-20 2015-02-03 ProteinSimple Electrophoresis standards, methods and kits
US20080017512A1 (en) * 2006-07-24 2008-01-24 Bordunov Andrei V Coatings for capillaries capable of capturing analytes
WO2008057605A2 (fr) * 2006-11-10 2008-05-15 Quidel Corporation Milieu d'extraction de nucléoprotéines et sa méthode d'utilisation
US20090023156A1 (en) * 2007-07-20 2009-01-22 Voss Karl O Methods and reagents for quantifying analytes
US10107782B2 (en) 2008-01-25 2018-10-23 ProteinSimple Method to perform limited two dimensional separation of proteins and other biologicals
JP2011206049A (ja) 2010-03-08 2011-10-20 Sumio Sugano 壊死マーカー及びその用途
US9804079B2 (en) 2012-04-19 2017-10-31 ProteinSimple Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates
US9766206B2 (en) 2013-09-27 2017-09-19 ProteinSimple Apparatus, systems, and methods for capillary electrophoresis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US4882268A (en) * 1985-12-24 1989-11-21 Massachusetts Institute Of Technology Method for determining tissue of origin and degree of malignancy of tumor cells
US5273877A (en) * 1985-12-24 1993-12-28 Massachusetts Institute Of Technology Non-histological cell type determination
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4937185A (en) * 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
WO1989006697A1 (fr) * 1988-01-19 1989-07-27 The University Of Sydney Detection de la mort de cellules
US5017474A (en) * 1988-02-12 1991-05-21 Eastman Kodak Company Wash solution, test kit and method for the determination of an immunological ligand
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
ATE143056T1 (de) * 1990-05-01 1996-10-15 Isis Pharmaceuticals Inc Identifikation von neuen medikamenten und reagenzien
DE69230890T2 (de) * 1991-10-31 2000-12-07 Matritech Inc Bestimmung von nukleären matrixproteinen in flüssigkeiten
AU2890492A (en) * 1991-11-08 1993-06-07 University Of Saskatchewan Acute phase proteins for detection and prognosis of infection and tissue damage
AU4288593A (en) * 1992-04-15 1993-11-18 Brigham And Women's Hospital Method and composition for the detection of lesions
DE69333377T2 (de) * 1992-06-22 2004-10-21 Matritech Inc Neuartige marker maligner zelltypen in der inneren nukleären matrix

Also Published As

Publication number Publication date
US20050059026A1 (en) 2005-03-17
ES2147555T3 (es) 2000-09-16
US20060127941A1 (en) 2006-06-15
US5965376A (en) 1999-10-12
WO1993009437A2 (fr) 1993-05-13
DE69230890T2 (de) 2000-12-07
US20030096304A1 (en) 2003-05-22
US5989826A (en) 1999-11-23
DE69230890D1 (de) 2000-05-11
CA2122473C (fr) 2001-01-23
US5840503A (en) 1998-11-24
US6740494B2 (en) 2004-05-25
EP0642668B1 (fr) 2000-04-05
JPH07500671A (ja) 1995-01-19
EP0642668A1 (fr) 1995-03-15
JP3190042B2 (ja) 2001-07-16
AU658257B2 (en) 1995-04-06
WO1993009437A3 (fr) 1993-06-10
US6410247B1 (en) 2002-06-25
ATE191567T1 (de) 2000-04-15
US6162608A (en) 2000-12-19
AU3123593A (en) 1993-06-07

Similar Documents

Publication Publication Date Title
CA2122473A1 (fr) Dosage en phase liquide de proteines de la matrice nucleaire
ATE205602T1 (de) Verfahren und gerät zum nachweis und zur quantifizierung von glukose in körperflüssigkeiten
WO1998053076A3 (fr) Composes permettant de diagnostiquer la tuberculose et leurs procedes d'utilisation
WO1999049807A3 (fr) Procede et dispositif pour realiser une modification biologique d'un fluide
CA2203885A1 (fr) Traitement de solutions d'hematies avec des agents antiviraux
FI854488A (fi) Kontrastmedel.
WO1998016645A3 (fr) Composes et procedes pour diagnostiquer la tuberculose
AU8423991A (en) Biological fluid specimen collection bag
AU3575089A (en) Method of detecting bacteria in urine
NO903988L (no) Anordning og fremgangsmaate for evaluering av et legemes evne til aa utstoete et produkt, samt dens anvendelse paa en stenproeve.
Schaal Laboratory diagnosis of actinomycete diseases.
NO177463C (no) STLV-III-beslektede polypeptider, diagnostiske prövesett og in vitro analysefremgangsmåte for påvisning av anti-HIV-2-antistoffer i kroppsvæskepröve
WO2001044438A3 (fr) Bacterie rickettsia pulicis methode de diagnostic serologique
GB9312315D0 (en) Leukocyte adhesion assay
Isaacson et al. Assays of antimicrobial substances.
CA2172243A1 (fr) Methode pour l'analyse quantitative des liquides organiques
EP0184919A3 (fr) Trousse diagnostique pour détecter les amines, sa production et procédé pour détecter les amines
AU4294089A (en) Process for the detection of legionella antigens in body fluids and the like, as well as a test kit for performing the process
EP0782863A4 (fr) Reactif anticorpal pour la detection des anevrismes dissequants de l'aorte et utilisation de ce reactif
SU1304398A1 (ru) Штамм VIвRIо NaG 62 серовара,используемый дл приготовлени диагностической сыворотки против вибрионов 62 серовара
DE69013823D1 (de) Hydraulischer Fühler zum Nachweis und Lokalisierung des Quenchens in Supraleiter.
FR2791357B1 (fr) Diagnostic de la maladie de whipple
AU2088188A (en) Process and device for examining whole blood, other body fluids and other biological fluids
IT8748764A0 (it) Terreno di coltura per l'identifica zione rapida di candida albicansnegli esami clinici microbiologici
IT8848733A0 (it) Terreno di coltura per l'identifica zione dei microorganismi appartenenti al gruppo degli emofili negli esami clinici microbiologici

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry